What Could AbbVie Stock Be Worth In Three Years?
For questions about this article or underlying research, email help@trefis.com.
AbbVie (ABBV) stock returned 40.6% in the year to November 4, 2026, against 14.9% for the S&P 500. You may hold it after that run or be thinking of buying. Either way, the company’s profit is hard to project because AbbVie’s net income more than quadrupled in the twelve months to September 2026 from a year earlier. So what would a share bought today be worth if AbbVie keeps growing?
Each AbbVie Share Would Be Worth About $328
Based on AbbVie’s own figures, a scenario shows that a share bought at $294.83 on November 4, 2026, would be worth about $328.03 three years later. That represents an 11.3% upside before dividends.
In that scenario, sales grow 9.1% a year, a rate that equals 85% of AbbVie’s latest twelve-month pace of 10.7%. The net margin ends at a blend of 70% of today’s level and 30% of its average at the twelve quarter ends before the latest one. The P/E stays at today’s level. This multiple sits below its 69.5 average at ten quarter ends from December 2023 to September 2026, leaving out readings above 100. The share count stays at today’s level. AbbVie’s diluted count rose about 0.06% over the three years to September 2026, and if that pattern went on, each share would get slightly less.
Here is how AbbVie today compares with the scenario three years on.
| Today | In three years (scenario) | |
|---|---|---|
| Revenue | $66.0 billion | $85.7 billion |
| Net margin | 15.7% | 13.4% |
| Earnings | $10.3 billion | $11.5 billion |
| P/E | 50.4 | 50.4 |
| Share price | $294.83 | $328.03 |
Higher sales produce all of the gain, though the scenario’s lower net margin offsets part of it. None of the upside comes from the P/E. Most of AbbVie’s sales growth comes from its immunology drugs, led by Skyrizi and Rinvoq. Immunology revenue approached $9.2 billion in the third quarter of fiscal 2026, up 16.6% on an operational basis.
Can AbbVie Keep Its Sales Growing This Fast?
On its October 30, 2026 call, management said it expects to deliver top-tier growth again in 2027. Management also said Skyrizi and Rinvoq are adding about $6 billion of sales combined in 2026, even with more competition. Skyrizi alone sold $17.6 billion in fiscal 2025, an increase of 49.9% from a year earlier.
Those gains have to keep outrunning AbbVie’s losses elsewhere. Humira sales fell 30.6% in the third quarter of fiscal 2026, to $683 million. Management put this decline down to continued competition from biosimilar copies. Management raised its fiscal 2026 revenue outlook to about $67.8 billion. Three of that year’s quarters are already reported, so the outlook is mostly results already in hand, not a pace for later years.
How AbbVie’s Upside Changes Under Other Assumptions
Each row below changes one assumption while keeping the other two as they are in the scenario.
| If instead | Upside |
|---|---|
| Nothing changes (the scenario) | 11.3% |
| Revenue growth of 7.1% a year instead of 9.1% | 5.3% |
| Net margin back at its past average of 8.2% in year three instead of 13.4% | -32.0% |
| 5 years at the same assumptions instead of 3 | 32.4% |
The scenario bases its sales growth on AbbVie’s fastest pace of the past three years. Twelve-month revenue growth was 0.7% in the period to September 2024 and 7.4% a year later. Today’s net margin is also nearly twice its average at the twelve quarter ends from September 2023 to June 2026, so the margin in the scenario is set lower.
Taken one at a time, three years of owning AbbVie stock would return nothing, before dividends, if revenue growth slowed to 5.3% a year. That compares with 10.7% in the twelve months to September 2026. Owning the stock would also return nothing if the net margin fell to 12.1% in year three, against 15.7% today. The same holds if the P/E fell to 45.3, against 50.4 at the November 4, 2026 close.
AbbVie’s twelve-month net margin is the measure to watch when the company reports its fiscal fourth quarter, expected in February 2027.
Sitting On A Big Gain In AbbVie?
After a run like this, the hard questions are personal: hold, trim or sell, and the tax on each. Our partner advisory firm offers a free strategy review of ways to keep part of the upside, protect the rest and spread the tax over years.
Request A Free Strategy Review
Spot an error or want more like this? Tell us in 10 seconds.